We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
News

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
News

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Elusys Therapeutics and Lonza Sales AG entered into an agreement for the production of Anthim™, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection.

Under this agreement, Lonza will provide process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.

"Elusys is pleased to initiate a partnership with Lonza for the production of Anthim. Lonza has considerable experience in large-scale manufacturing of monoclonal antibodies and a well-established reputation with regulatory agencies for the production of licensed products," commented James Porter, Vice President of Development and Manufacturing at Elusys.

"Elusys has developed a very promising antibody therapeutic and we are proud to be able to support the further development of Anthim towards its commercial use," added Dr. Stephan Kutzer, Head of Lonza Biopharmaceuticals.
Advertisement